Guangzhou Innogen Pharmaceutical Group Co Ltd
Company Profile
Business description
Guangzhou Innogen Pharmaceutical Group Co Ltd is a company in Asia to commercialize an innovative, humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It has commercialized Efsubaglutide Alfa (brand name: Diabegone), its Core Product, for the treatment of type 2 diabetes (T2D) in China. Its core business model is to discover, develop and commercialize innovative therapies for diabetes and other metabolic diseases. The company has built a pipeline of drug candidates targeting diabetes and other metabolic diseases.
Contact
No. 2 Tengfei Second Street
Room 409, Building H Self-numbered Creative Building
China-Singapore Guangzhou Knowledge City
Huangpu District, Guangdong Province
Guangzhou
CHNSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
193
Stocks News & Analysis
stocks
Chart of the Week: Has gold reached bear market territory?
stocks
Fair value upgrade for this ASX income player
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,885.60 | 59.90 | 0.68% |
| CAC 40 | 7,816.94 | 44.49 | 0.57% |
| DAX 40 | 22,680.04 | 117.16 | 0.52% |
| Dow JONES (US) | 46,341.51 | 1,125.37 | 2.49% |
| FTSE 100 | 10,176.45 | 48.49 | 0.48% |
| HKSE | 25,349.78 | 561.64 | 2.27% |
| NASDAQ | 21,590.63 | 795.99 | 3.83% |
| Nikkei 225 | 53,600.76 | 2,537.04 | 4.97% |
| NZX 50 Index | 12,825.87 | 86.24 | -0.67% |
| S&P 500 | 6,528.52 | 184.80 | 2.91% |
| S&P/ASX 200 | 8,671.80 | 53.10 | 0.62% |
| SSE Composite Index | 3,943.01 | 51.15 | 1.31% |